It Seems Zai Lab Limited (ZLAB) Will Go Down. Formed A Few Months Bearish Wedge Down Pattern

May 17, 2018 - By Alfred Lee

The stock of Zai Lab Limited (ZLAB) formed a down wedge with $19.89 target or 3.00 % below today’s $20.50 share price. The 9 months wedge indicates high risk for the $1.04B company. If the $19.89 price target is reached, the company will be worth $31.08 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 2.19% or $0.46 during the last trading session, reaching $20.5. About 33,133 shares traded. Zai Lab Limited (NASDAQ:ZLAB) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

More important recent Zai Lab Limited (NASDAQ:ZLAB) news were published by: which released: “Zai Lab Limited to Announce Full Year 2017 Financial Results” on April 24, 2018, also published article titled: “Zai Lab Limited Announces Presentations at May Investor Conferences”, published: “Zai Lab Reports Full Year 2017 Financial Results and Corporate Update” on May 02, 2018. More interesting news about Zai Lab Limited (NASDAQ:ZLAB) was released by: and their article: “Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic …” with publication date: April 25, 2018.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. The company has market cap of $1.04 billion. The Company’s drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: